Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
HypercholesterolemiaDyslipidemia
Interventions
DRUG

Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.

Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.

DRUG

Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.

Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.

Trial Locations (7)

Unknown

Centro de Pesquisas em Diabetes e Doenças Endócrino-Metabólicas- UFC, Fortaleza

Centro de Pesquisas Médicas Básica e Clínica, Recife

CCBR Brasil Centro de Pesquisas e Análises Clínicas, Rio de Janeiro

CEPIC Centro Paulista de Investigação Clínica, São Paulo

FGM - Clínica Paulista de Doenças Cardiovasculares, São Paulo

Hospital do Rim e Hipertensão, São Paulo

Universidade Federal de São Paulo, São Paulo

All Listed Sponsors
lead

Ache Laboratorios Farmaceuticos S.A.

INDUSTRY

NCT01420549 - Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia | Biotech Hunter | Biotech Hunter